Introduction of novel agents in the treatment of primary CNS lymphoma

Christian Grommes, Lakshmi Nayak, Han W Tun, Tracy T. Batchelor

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Novel insights into the pathophysiology of primary central nervous system lymphoma (PCNSL) have identified the B-cell receptor and Toll-like receptor pathway as well as immune evasion and suppressed tumor immune microenvironment as a key mechanism in the pathogenesis of PCNSL. Small molecules and novel agents targeting these aberrant pathways have been introduced into clinical trials targeting the recurrent or refractory PCNSL patient population. Agents like the Bruton tyrosine kinase (BTK) inhibitor ibrutinib or immunomodulatory drugs (IMiDs) like pomalidomide and lenalidomide have shown promising high response rates in the salvage setting. Here, we give an overview about the recent, exciting developments in PCNSL and summarize the results of clinical trials using novel agents in the recurrent and refractory salvage setting, which include immune checkpoint inhibitors, IMiDs, as well as BTK, phosphatidylinositol-3 kinase, and mammalian target of rapamycin inhibitors.

Original languageEnglish (US)
Pages (from-to)306-313
Number of pages8
JournalNeuro-oncology
Volume21
Issue number3
DOIs
StatePublished - Jan 1 2019

Fingerprint

Lymphoma
Central Nervous System
Clinical Trials
Phosphatidylinositol 3-Kinase
Immune Evasion
Tumor Microenvironment
Toll-Like Receptors
Sirolimus
Therapeutics
B-Lymphocytes
Pharmaceutical Preparations
Population
Agammaglobulinaemia tyrosine kinase

Keywords

  • BTK
  • IMiD
  • Immune checkpoint inhibition
  • PCNSL
  • Targeted agents

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Introduction of novel agents in the treatment of primary CNS lymphoma. / Grommes, Christian; Nayak, Lakshmi; Tun, Han W; Batchelor, Tracy T.

In: Neuro-oncology, Vol. 21, No. 3, 01.01.2019, p. 306-313.

Research output: Contribution to journalArticle

Grommes, Christian ; Nayak, Lakshmi ; Tun, Han W ; Batchelor, Tracy T. / Introduction of novel agents in the treatment of primary CNS lymphoma. In: Neuro-oncology. 2019 ; Vol. 21, No. 3. pp. 306-313.
@article{0e2d53308eb9460cad9492807a2f6304,
title = "Introduction of novel agents in the treatment of primary CNS lymphoma",
abstract = "Novel insights into the pathophysiology of primary central nervous system lymphoma (PCNSL) have identified the B-cell receptor and Toll-like receptor pathway as well as immune evasion and suppressed tumor immune microenvironment as a key mechanism in the pathogenesis of PCNSL. Small molecules and novel agents targeting these aberrant pathways have been introduced into clinical trials targeting the recurrent or refractory PCNSL patient population. Agents like the Bruton tyrosine kinase (BTK) inhibitor ibrutinib or immunomodulatory drugs (IMiDs) like pomalidomide and lenalidomide have shown promising high response rates in the salvage setting. Here, we give an overview about the recent, exciting developments in PCNSL and summarize the results of clinical trials using novel agents in the recurrent and refractory salvage setting, which include immune checkpoint inhibitors, IMiDs, as well as BTK, phosphatidylinositol-3 kinase, and mammalian target of rapamycin inhibitors.",
keywords = "BTK, IMiD, Immune checkpoint inhibition, PCNSL, Targeted agents",
author = "Christian Grommes and Lakshmi Nayak and Tun, {Han W} and Batchelor, {Tracy T.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1093/neuonc/noy193",
language = "English (US)",
volume = "21",
pages = "306--313",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Introduction of novel agents in the treatment of primary CNS lymphoma

AU - Grommes, Christian

AU - Nayak, Lakshmi

AU - Tun, Han W

AU - Batchelor, Tracy T.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Novel insights into the pathophysiology of primary central nervous system lymphoma (PCNSL) have identified the B-cell receptor and Toll-like receptor pathway as well as immune evasion and suppressed tumor immune microenvironment as a key mechanism in the pathogenesis of PCNSL. Small molecules and novel agents targeting these aberrant pathways have been introduced into clinical trials targeting the recurrent or refractory PCNSL patient population. Agents like the Bruton tyrosine kinase (BTK) inhibitor ibrutinib or immunomodulatory drugs (IMiDs) like pomalidomide and lenalidomide have shown promising high response rates in the salvage setting. Here, we give an overview about the recent, exciting developments in PCNSL and summarize the results of clinical trials using novel agents in the recurrent and refractory salvage setting, which include immune checkpoint inhibitors, IMiDs, as well as BTK, phosphatidylinositol-3 kinase, and mammalian target of rapamycin inhibitors.

AB - Novel insights into the pathophysiology of primary central nervous system lymphoma (PCNSL) have identified the B-cell receptor and Toll-like receptor pathway as well as immune evasion and suppressed tumor immune microenvironment as a key mechanism in the pathogenesis of PCNSL. Small molecules and novel agents targeting these aberrant pathways have been introduced into clinical trials targeting the recurrent or refractory PCNSL patient population. Agents like the Bruton tyrosine kinase (BTK) inhibitor ibrutinib or immunomodulatory drugs (IMiDs) like pomalidomide and lenalidomide have shown promising high response rates in the salvage setting. Here, we give an overview about the recent, exciting developments in PCNSL and summarize the results of clinical trials using novel agents in the recurrent and refractory salvage setting, which include immune checkpoint inhibitors, IMiDs, as well as BTK, phosphatidylinositol-3 kinase, and mammalian target of rapamycin inhibitors.

KW - BTK

KW - IMiD

KW - Immune checkpoint inhibition

KW - PCNSL

KW - Targeted agents

UR - http://www.scopus.com/inward/record.url?scp=85066940055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066940055&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noy193

DO - 10.1093/neuonc/noy193

M3 - Article

C2 - 30423172

AN - SCOPUS:85066940055

VL - 21

SP - 306

EP - 313

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 3

ER -